PharmaShots | Incisive News in 3 Shots

Subscribe Now

Lymphoblastic Leukemia

Amgen Reports Results of Blincyto (blinatumomab) in P-III Study for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients

Amgen Reports Results of Blincyto (blinatumomab) in P-III Study for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients

March 3, 2021

Kite Reports P-I/II Study (ZUMA-3) Results of Tecartus (brexucabtagene autoleucel) for B-Cell Acute Lymphoblastic Leukemia

Kite Reports P-I/II Study (ZUMA-3) Results of Tecartus (brexucabtagene autoleucel) for B-Cell Acute Lymphoblastic Leukemia

February 10, 2023

$Kite’s Tecartus Receives EC’s Approval for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia$

Kite’s Tecartus Receives EC’s Approval for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

September 7, 2022

$Kite Receives CHMP Positive Opinion of Tecartus (brexucabtagene autoleucel) for Relapsed or Refractory Acute Lymphoblastic Leukemia$

Kite Receives CHMP Positive Opinion of Tecartus (brexucabtagene autoleucel) for Relapsed or Refractory Acute Lymphoblastic Leukemi...

July 25, 2022

Kite's Tecartus Receives the US FDA's Approval as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lym...

October 4, 2021

Jazz's Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Receives the US FDA's Approval for Acute Lymphoblastic Leukem...

July 1, 2021

Daiichi Sankyo Reports First patient Dosing in P- I/II Trial of DS-1594 to Treat Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Daiichi Sankyo Reports First patient Dosing in P- I/II Trial of DS-1594 to Treat Acute Myeloid Leukemia and Acute Lymphoblastic Le...

April 8, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us